Cassava Sciences(US:SAVA)2026-03-12 12:15Financial Performance - Net loss for 2025 was $91.0 million, or $1.88 per share, compared to a net loss of $24.3 million, or $0.53 per share in 2024[2] - Cash and cash equivalents were $95.5 million as of December 31, 2025, down from $128.6 million at the end of 2024[7] - The company estimates net cash use in operations for the first half of 2026 to be in a range from $14 to $17 million, plus a $31.25 million estimated loss contingency related to securities litigation[3] Expenses - Research and development expenses decreased to $26.6 million in 2025, a 62% reduction from $69.6 million in 2024[8] - General and administrative expenses decreased to $68.8 million in 2025, down 4% from $71.8 million in 2024[8] - The total operating expenses for 2025 were $95.4 million, compared to $141.4 million in 2024[20] Future Plans - The company plans to submit a response to the FDA regarding the clinical hold on its TSC-related epilepsy program as soon as practicable[4] - The company is focused on developing novel medicines to modulate the filamin A protein for CNS disorders, including TSC-related epilepsy[7] Share Information - Total shares outstanding as of March 9, 2026, were 48.3 million[7] - The company estimates cash at June 30, 2026, to be in a range from $47 to $50 million[3]